{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T06:55:29Z","timestamp":1777877729744,"version":"3.51.4"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"34","license":[{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,22]]},"abstract":"<jats:p>\n                    Metastatic head and neck tumors, especially metastatic head and neck squamous cell carcinoma, have a poor prognosis and are complex to treat. Although chemotherapy remains the standard first-line treatment option, it is often associated with tumor resistance and side effects. The aim of this retrospective cohort study was to evaluate the efficacy and safety of the combination of panitumumab and paclitaxel in the treatment of metastatic head and neck tumors. The study divided patients into experimental (panitumumab with paclitaxel\u2005+\u2005cisplatin treatment) and control (paclitaxel\u2005+\u2005cisplatin treatment) groups, with the primary assessment of objective remission rate and the secondary endpoints of disease control rate, progression-free survival (PFS), and overall survival (OS). The results of the study showed that there was no significant difference in short-term efficacy between the experimental group and the control group (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&gt;\u2005.05), but the PFS (median value: 10.2 months) and OS (median value: 15.4 months) of the experimental group were significantly better than those of the control group (median value of PFS: 8.1 months, median value of OS: 11.8 months), and the difference was statistically significant (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001). The incidence of adverse events was higher in the experimental group than in the control group, especially in electrolyte disorders and skin rash, and the difference was statistically significant (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.05), but most of these adverse events were tolerable. In conclusion, the combination of panitumumab and paclitaxel was associated with prolonged PFS and OS in patients with metastatic head and neck tumors, with manageable safety and tolerability compared to standard chemotherapy. These findings suggest that this regimen may represent a potential treatment option and warrant further validation in prospective, randomized studies.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000043842","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T21:00:53Z","timestamp":1756846853000},"page":"e43842","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Clinical efficacy analysis of the combination of panitumumab and paclitaxel in the first-line treatment of metastatic head and neck tumors"],"prefix":"10.1097","volume":"104","author":[{"given":"Juan","family":"Wang","sequence":"first","affiliation":[{"name":"Chongqing Preschool Education College, Wanzhou District, Chongqing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Xiang","sequence":"additional","affiliation":[{"name":"Chongqing Preschool Education College, Wanzhou District, Chongqing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3945-4602","authenticated-orcid":false,"given":"Shen","family":"Zhou","sequence":"additional","affiliation":[{"name":"Clinical Laboratory Center, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Yang","sequence":"additional","affiliation":[{"name":"Head and Neck Cancer Center, Chongqing University Cancer Hospital, Shapingba District, Chongqing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20260430","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-20260430","doi-asserted-by":"crossref","first-page":"109282","DOI":"10.1016\/j.isci.2024.109282","article-title":"Global burden of head and neck cancers from 1990 to 2019.","volume":"27","author":"Zhou","year":"2024","journal-title":"iScience"},{"key":"R3-20260430","first-page":"721","article-title":"Breast cancer: an overview of current therapeutic strategies, challenge, and perspectives.","volume":"15","author":"Wang","year":"2023","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"R4-20260430","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"R5-20260430","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1200\/JCO.23.02625","article-title":"Pembrolizumab plus carboplatin and paclitaxel as first-line therapy for recurrent\/metastatic head and neck squamous cell carcinoma (KEYNOTE-B10): a single-arm phase IV Trial.","volume":"42","author":"Dzienis","year":"2024","journal-title":"J Clin Oncol"},{"key":"R6-20260430","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/s41571-021-00501-4","article-title":"Evolution of systemic therapy for stages I\u2013III non-metastatic non-small-cell lung cancer.","volume":"18","author":"Chaft","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"R7-20260430","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41568-022-00531-9","article-title":"Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment.","volume":"23","author":"Ruffin","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"R8-20260430","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma.","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"key":"R9-20260430","doi-asserted-by":"crossref","first-page":"964442","DOI":"10.3389\/fimmu.2022.964442","article-title":"The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers.","volume":"13","author":"Tang","year":"2022","journal-title":"Front Immunol"},{"key":"R10-20260430","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy.","volume":"35","author":"Naidoo","year":"2017","journal-title":"J Clin Oncol"},{"key":"R11-20260430","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1001\/jama.2023.4428","article-title":"Panitumumab vs bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer: a randomized clinical trial.","volume":"329","author":"Watanabe","year":"2023","journal-title":"JAMA"},{"key":"R12-20260430","doi-asserted-by":"crossref","first-page":"eabg6428","DOI":"10.1126\/scitranslmed.abg6428","article-title":"Targeting AKR1B1 inhibits glutathione de novo synthesis to overcome acquired resistance to EGFR-targeted therapy in lung cancer.","volume":"13","author":"Zhang","year":"2021","journal-title":"Sci Transl Med"},{"key":"R13-20260430","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2217\/fon-2019-0748","article-title":"Encorafenib, binimetinib and cetuximab combined therapy for patients with BRAFV600E mutant metastatic colorectal cancer.","volume":"16","author":"Huijberts","year":"2020","journal-title":"Future Oncol"},{"key":"R14-20260430","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40265-023-01835-2","article-title":"Treating head and neck cancer in the age of immunotherapy: a 2023 Update.","volume":"83","author":"Bhatia","year":"2023","journal-title":"Drugs"},{"key":"R15-20260430","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.21.02508","article-title":"Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 Study.","volume":"41","author":"Harrington","year":"2023","journal-title":"J Clin Oncol"},{"key":"R16-20260430","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/CAD.0000000000000086","article-title":"Taxanes in cancer of the head and neck.","volume":"25","author":"Misiukiewicz","year":"2014","journal-title":"Anticancer Drugs"},{"key":"R17-20260430","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer.","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"key":"R18-20260430","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jhep.2022.03.039","article-title":"Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma.","volume":"77","author":"Chuah","year":"2022","journal-title":"J Hepatol"},{"key":"R19-20260430","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13045-021-01164-5","article-title":"Combination strategies to maximize the benefits of cancer immunotherapy.","volume":"14","author":"Zhu","year":"2021","journal-title":"J Hematol Oncol"},{"key":"R20-20260430","doi-asserted-by":"crossref","first-page":"103476","DOI":"10.1016\/j.esmoop.2024.103476","article-title":"A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody.","volume":"9","author":"Koyama","year":"2024","journal-title":"ESMO Open"},{"key":"R21-20260430","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"key":"R22-20260430","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.otc.2021.04.005","article-title":"Epidermal growth factor receptor-targeted therapy for head and neck cancer.","volume":"54","author":"Trivedi","year":"2021","journal-title":"Otolaryngol Clin North Am"},{"key":"R23-20260430","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance.","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu Rev Pathol"},{"key":"R24-20260430","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"issue":"Suppl 12","key":"R25-20260430","first-page":"8","article-title":"The role of paclitaxel in the treatment of head and neck cancer.","volume":"22","author":"Vokes","year":"1995","journal-title":"Semin Oncol"},{"key":"R26-20260430","doi-asserted-by":"crossref","first-page":"114458","DOI":"10.1016\/j.biopha.2023.114458","article-title":"Autophagy in cancer resistance to paclitaxel: development of combination strategies.","volume":"161","author":"\u0160kubn\u00edk","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"R27-20260430","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/cac2.12327","article-title":"KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1\/PD-L1 immunotherapy in non-small cell lung cancer.","volume":"42","author":"Liu","year":"2022","journal-title":"Cancer Commun (Lond)"},{"key":"R28-20260430","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol"},{"key":"R29-20260430","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1053\/j.gastro.2020.03.018","article-title":"Combination of PD-1 inhibitor and OX40 agonist induces tumor rejection and immune memory in mouse models of pancreatic cancer.","volume":"159","author":"Ma","year":"2020","journal-title":"Gastroenterology"},{"key":"R30-20260430","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events.","volume":"83","author":"Geisler","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"R31-20260430","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41577-023-00982-7","article-title":"New immune cell engagers for cancer immunotherapy.","volume":"24","author":"Fenis","year":"2024","journal-title":"Nat Rev Immunol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000043842","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:00:12Z","timestamp":1777590012000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000043842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,22]]},"references-count":31,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000043842","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,22]]},"assertion":[{"value":"2025-05-24","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-22","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}